Login to Your Account

Dauntless Pharmaceuticals Inc. had a smooth initial take-off, fueled by a $12 million series A supporting a single asset, and that's just the way the San Diego-based company and backer Sofinnova Ventures plan to keep rolling off the runway.
Astrazeneca plc spinout Entasis Therapeutics Inc. has come in from the cold with a portfolio of drugs that previously resided in the pharma's anti-infectives pipeline and a fistful of cash from its erstwhile parent.
Nanocell firm Engeneic Ltd. started using cancer immunotherapy in its unique way "before anyone else, because we have bacterially derived particles," Managing Director Jennifer MacDiarmid told BioWorld Today.
More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: